Emerging candidate biomarkers for Parkinson's disease: a review.
Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment affecting more than 1% of the over-65 population. In spite of considerable progress in identifying the genetic and biochemical basis of PD, to date the diagnosis remains clinical and disease-modifying therapies continue to be elusive. A cornerstone in recent PD research is the investigation of biological markers that could help in identifying at-risk population or to track disease progression and response to therapies. Although none of these parameters has been validated for routine clinical practice yet, however some biochemical candidates hold great promise for application in PD patients, especially in the early stages of disease, and it is likely that in the future the diagnosis of PD will require a combination of genetic, imaging and laboratory data. In this review we discuss the most interesting biochemical markers for PD (including the "-omics" techniques), focusing on the methodological challenges in using ex vivo blood/CSF/tissue-based biomarkers and suggesting alternative strategies to overcome the difficulties that still prevent their actual use.
Department of Neurology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.
Enrico
E
Saracchi
Neurology Department, Azienda Ospedaliera di Lodi, 26900 Lodi, Italy.
Silvia
S
Fermi
Department of Neurology, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.
Laura
L
Brighina
DJ-1; Parkinson’s disease; biomarkers; premotor; proteomic; α-synuclein